URGENT PANDEMIC INFORMATION

In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List


Next Generation Cardiovascular Drug Development Summit


Date
Apr 25, 2023 - 09:00 AM - Apr 27, 04:00 PM
Organizer
Hanson Wade
Venue
Hyatt Regency Boston
Location
One Ave. de Lafayette,

Boston,
Massachusetts,
US,
ZIP: 02111
Phone: +1 617 455 4188

Ticket Price: Drug Developer - Conference Only: USD 2999.00, Academic and Research - Conference Only: USD 2599.00, Solution Provider - Conference Only: USD 3799.00


Are you up to date on the latest research and developments in novel biologics to enhance regenerative and precision cardiovascular therapeutics?

Don't miss the Next Generation Cardiovascular Drug Development Summit, coming to Boston on April 25-27 as the only industry-focused meeting dedicated to leveraging novel cell and gene therapies using mRNA, CRISPR/Cas9 and iPSCs for cardiovascular disease.

This inaugural summit will delve deep into the understanding of genetic components of cardiovascular disease, utilisation of imaging biomarkers, delivery of precise cardiac therapeutics, optimization of preclinical animal models, and overcoming off-target genome editing to mitigate against toxicity and long-term effects and unlock the potential of novel biologics.

With 3 days of abundant insights into the latest breakthroughs and research and a faculty of world-class speakers pioneering the next wave of novel and precise cardiovascular therapeutics, this is biopharma's unmissable meeting for the expedition of treatment for cardiovascular disease patients.

URLs:
Brochure: https://go.evvnt.com/1492007-0?pid=1052
Tickets: https://go.evvnt.com/1492007-1?pid=1052


Speaker Details


Christopher O'Donnell, Global Head Cardiovascular and Metabolism Translational Medicine, Novartis Institutes of Biomedical Research, Denise Yates, Director, Biomarker Development, Cardiovascular and Imaging, Novartis Institutes of Biomedical Research, Eric Adler, Chief Scientific Officer, LEXEO Therapeutics, Haig Aghajanian, Co-founder and Vice President, Research, Capstan Therapeutics, Ibrahim Domian, Vice President - Development, BlueRock Therapeutics, Jeff Madwed, Executive Director, Juvenescence Limited, John Zuris, Director, Editing Technologies, Editas Medicine, Jonathan Plehn, Chief Medical Officer, Sardocor Corporation, Julie Phillips, Senior Scientist, BioCardia, Kiran Musunuru, Professor of Medicine, Perelman School of Medicine at the University of Pennsylvania, Lei Zhao, Senior Director, Immunology, Cardiovascular and Fibrosis Translational Early Development, Bristol Myers Squibb, Lior Zangi, Associate Professor of Medicine, Cardiology and Genetics and Genomic Sciences, Icahn Genomics Institute at Mount Sinai, Masahiro Murakami, Executive Director - Diabetes and Cardiovascular, Eli Lilly and Co., Nolan Townsend, Chief Executive Officer, LEXEO Therapeutics, Peter Altman, Chief Executive Officer, BioCardia, Pooja Agarwal, Head of Gene Therapy and Research, BioMarin Pharmaceutical Inc., Steven Lubitz, Director in Translational Medicine, Novartis Institutes of Biomedical Research, Takehiko Kaneko, Chief Medical Officer, Heartseed Inc, Tim Hoey, Chief Scientific Officer, Tenaya Therapeutics, Waheed Jamal, Vice President, Global Head of Cardiovascular and Metabolic Medicine, Boehringer Ingelheim

Event Categories
Keywords: Health , pharmaceutical , Conferences , medicine, science




Comments








Events Calendar

SunMonTueWedThuFriSat
26 27 28 29 30 31 1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 1 2 3 4 5 6

Newsletters

VIP Life Time Subscription to our Newsletters!
$399.99
$299.99